PMID- 31040711
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 12
DP  - 2019
TI  - Adherence, satisfaction, and experience with metformin 500 mg prolonged release 
      formulation in Indian patients with type 2 diabetes mellitus: a postmarketing 
      observational study.
PG  - 147-159
LID - 10.2147/IJGM.S179622 [doi]
AB  - PURPOSE: The aim of this study was to understand patient adherence, satisfaction, 
      and experience with the smaller sized metformin 500 mg prolonged release (PR) 
      tablet that has been manufactured with the help of technological advancement 
      (Gluformin I 500 mg), in comparison with metformin 500 mg extended-release (ER) 
      tablet, in patients with type 2 diabetes mellitus (T2DM). PATIENTS AND METHODS: 
      In this postmarketing observational study, T2DM patients who were on a stable 
      dose of metformin 500 mg PR tablet for at least 1 month and had previously 
      received metformin 500 mg ER tablet were recruited from 50 sites in India. The 
      medication adherence and patients' experience, satisfaction, and perception with 
      metformin 500 mg PR tablets were compared with metformin 500 mg ER tablets. The 
      patients' experience was determined based on the external appearance of tablet, 
      ease of swallowing, the presence of gastrointestinal discomfort, and ghost pill 
      effect. RESULTS: A total of 1,000 patients were enrolled. The majority had medium 
      adherence to metformin 500 mg PR tablet (54%) and did not report swallowing 
      difficulties (66.2%) due to its small size (64.4%) and oval shape (64.3%). The PR 
      formulation of metformin was more acceptable than ER formulation due to no 
      aftertaste (63%). The ghost pill effect was reported in 0.7% of patients with 
      metformin 500 mg PR tablet against 8.5% with ER tablet. More than 60% of patients 
      were "comfortable" (67.9%), had "much effect on their well-being" (61.8%), and 
      were "satisfied" (69%) with metformin 500 mg PR tablet compared with ER tablet. 
      Patient's dissatisfaction (42.7%) and taste (24.9%) were the common reasons cited 
      by physicians and patients, respectively, for changing the treatment from 
      metformin 500 mg ER to metformin 500 mg PR formulation. A total of 10 adverse 
      events (nonserious) were reported, and all of them were resolved. CONCLUSION: The 
      technologically advanced formulation of metformin 500 mg PR tablets is more 
      effective than that of metformin 500 mg ER tablets in improving adherence, 
      compliance, satisfaction, and perception to medication in Indian patients with 
      T2DM.
FAU - Kumar, K M Prasanna
AU  - Kumar KMP
AD  - Centre for Diabetes and Endocrine Care, Bangalore, Karnataka, India, 
      dr.kmpk@gmail.com.
FAU - Chawla, Manoj
AU  - Chawla M
AD  - Lina Diabetes Care and Mumbai Diabetes Research Centre, Mumbai, Maharashtra, 
      India.
FAU - Sanghvi, Ami
AU  - Sanghvi A
AD  - Sanghvi Eye and Diabetes Care Centre, Mumbai, Maharashtra, India.
FAU - Sastry, Nadiminty G
AU  - Sastry NG
AD  - Dr. Mohan's Diabetes Centre, Hyderabad, Telangana, India.
FAU - Kotla, Chaitanya
AU  - Kotla C
AD  - JP Endocrine and Research Institute, Hyderabad, Telangana, India.
FAU - Phatak, Sanjeev
AU  - Phatak S
AD  - Vijayratna Diabetes Diagnosis and Treatment, Ahmedabad, India.
FAU - Choudhari, Sanjay
AU  - Choudhari S
AD  - Abbott Healthcare Pvt. Ltd., Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20190409
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC6460999
OTO - NOTNLM
OT  - abdominal discomfort
OT  - medication adherence
OT  - metformin prolonged release tablet
OT  - noncompliance
OT  - treatment satisfaction
OT  - type 2 diabetes mellitus
COIS- Disclosure Dr Choudhari authored this publication as an employee of Abbott 
      Healthcare Pvt Ltd. The authors report no other conflicts of interest in this 
      work.
EDAT- 2019/05/02 06:00
MHDA- 2019/05/02 06:01
PMCR- 2019/04/09
CRDT- 2019/05/02 06:00
PHST- 2019/05/02 06:00 [entrez]
PHST- 2019/05/02 06:00 [pubmed]
PHST- 2019/05/02 06:01 [medline]
PHST- 2019/04/09 00:00 [pmc-release]
AID - ijgm-12-147 [pii]
AID - 10.2147/IJGM.S179622 [doi]
PST - epublish
SO  - Int J Gen Med. 2019 Apr 9;12:147-159. doi: 10.2147/IJGM.S179622. eCollection 
      2019.